botulinum toxin


Also found in: Dictionary, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to botulinum toxin

any of several neurotoxins that are produced by the anaerobic bacterium Clostridium botulinum

References in periodicals archive ?
Botulinum toxin A for treatment of sialorrhea in children: An effective, minimally invasive approach.
Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum.
Food and Drug Administration (FDA) approved the use of botulinum toxin A for overactive bladder due to neurological conditions, such as multiple sclerosis, spinal cord injury, stroke, and Parkinson's disease (Allergan, 2012; Yukhananov & Berkrot, 2011).
KEY WORDS: Benign essential blepharospasm botulinum toxin facial dystonia orbicularis oculi.
Early research suggests that there could be a role for botulinum toxin in combating itch by better understanding the interaction of the vascular system in inflammatory skin conditions.
It did not take long for botulinum toxin to become the new craze in cosmetic dermatology.
Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions.
Purified botulinum toxin (Type A) is a sterile vaccum dried neurotoxin complex produced from fermentation of hall strain clostridium botulinum(Type A) grown in medium containing Casein hydrolysate, glucose and yeast extract.
Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K: Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin.
Botulinum toxin A: First-line therapy for idiopathic detrusor overactivity.
Botulinum toxin works by temporarily blocking nerve signals that release such chemicals to certain muscles or glands.
Anatomy of the sweat glands, pharmacol-ogy of botulinum toxin, and distinctive syndromes associated with hyperhidrosis.
The toxin, dubbed BoNT/En, is the ninth botulinum toxin to be described.
The US Food and Drug Administration has granted orphan drug designation for Newark, California-based botulinum toxin products developer Revance Therapeutics, Inc.
The subject of the public contract is continuous deliveries of injections containing the active substance Botulinum toxin type A for 2 years.